Integra LifeSciences Holdings Beats on Both Top and Bottom Lines
Integra LifeSciences Holdings (NAS: IART) reported earnings on April 25. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Integra LifeSciences Holdings beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share contracted significantly.
Margins dropped across the board.
Integra LifeSciences Holdings booked revenue of $196.2 million. The 11 analysts polled by S&P Capital IQ predicted a top line of $192.7 million on the same basis. GAAP reported sales were 8.4% higher than the prior-year quarter's $181.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.71. The 14 earnings estimates compiled by S&P Capital IQ averaged $0.60 per share on the same basis. GAAP EPS of $0.23 for Q1 were 39% lower than the prior-year quarter's $0.38 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 61.9%, 300 basis points worse than the prior-year quarter. Operating margin was 8.9%, 600 basis points worse than the prior-year quarter. Net margin was 3.4%, 290 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $205.4 million. On the bottom line, the average EPS estimate is $0.70.
Next year's average estimate for revenue is $827.2 million. The average EPS estimate is $2.98.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 158 members out of 169 rating the stock outperform, and 11 members rating it underperform. Among 55 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 54 give Integra LifeSciences Holdings a green thumbs-up, and one gives it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is outperform, with an average price target of $38.23.
Over the decades, small-cap stocks, like Integra LifeSciences Holdings have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Integra LifeSciences Holdings to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.